EGM
MNPR icon

Engineers Gate Manager’s Monopar Therapeutics MNPR Stock Holding History

Engineers Gate Manager’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$243K Buy
4,434
+96
+2% +$5.8K ﹤0.01% 1819
2025
Q4 		$283K Buy
+4,338
New +$354K ﹤0.01% 1660

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Engineers Gate Manager's MNPR Position: Q1 2026 in Review

Engineers Gate Manager increased its Monopar Therapeutics (MNPR) stake by 2.2% in Q1 2026, buying an estimated $5.8K and bringing the position to 4,434 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #1819.

Engineers Gate Manager first reported a position in MNPR in Q4 2025 and has held it in 2 quarters since. The position peaked at $283K in Q4 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Engineers Gate Manager held 4,434 shares of Monopar Therapeutics worth $243K as of Q1 2026.
  • Engineers Gate Manager bought 96 Monopar Therapeutics shares in Q1 2026, an estimated $5.8K.
  • Monopar Therapeutics made up ﹤0.01% of Engineers Gate Manager's portfolio in Q1 2026, its #1819 holding.
  • Engineers Gate Manager first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Engineers Gate Manager's Monopar Therapeutics position peaked at $283K in Q4 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.